Osteoporosis: ACP Updated Treatment Guidelines
What is Osteoporosis?
Osteoporosis is a condition that increases bone fragility, making them prone to fracture. Loss of bone mass and deterioration of bone tissue is the result. The condition can affect all bones but the hip, wrist, and spine bones are more prone to breaking. Osteoporosis has become a growing problem in healthcare.
About half the population of people over 50 are at risk of osteoporosis-related fractures. Low bone density especially affects senior women. The American College of Physicians has found that women with osteoporosis should avoid estrogen therapy. When estrogen is given to women with osteoporosis an increased risk over health benefits is suggested.
With Osteoporosis, preventing bone fractures is a top priority. Hips and vertebrae are especially susceptible to fractures. ACP recommends patients with low bone density and osteoporosis be prescribing bisphosphonates risedronate, alendronate, or zoledronic acid. President of the ACP suggests the use of generic drugs whenever possible. Revisions of the 2008 guidelines have considered new evidence on treatments.
All the evidence with its risks and benefits should be considered by a doctor. These findings are significant, however, you should speak with your doctor before changing medications or stopping estrogen.